The FDA has granted an approval to a prefilled syringe for lanreotide (Somatuline Depot), which has been designed to enable healthcare providers to administer the injection easier, for the treatment of adults with unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETS).1
- Ipsen Announces US FDA Approval for Newly Designed Pre-Filled Syringe Somatuline Depot (lanreotide) [press release]. Ipsen. Published June 24, 2019. http://bit.ly/2IEyy8G. Accessed June 24, 2019.
- Caplin ME, Pavel M, Ćwikła JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371(3): 224-233). doi: 10.1056/NEJMoa1316158.
... to read the full story